Selinexor abrogates IKZF1 and c-MYC protein expression and induces growth inhibition in MM. (A) MMCLs were treated with selinexor at indicated doses for 48 hours. IKZF1 and c-MYC levels were detected using WB using β-actin as a loading control. The densities of the bands were measured using NIH ImageJ and normalized against β-actin. The immunoblot is representative of 3 independent experiments. (B) Selinexor inhibited MMCL proliferation in a dose-dependent manner. MMCLs were treated with different doses of selinexor for 4 days and the proliferation was detected using AQueous One Solution Cell Proliferation Assay (MTS). ∗P < .05 (C) MMCLs were treated with selinexor at indicated doses for 48 hours. eIF4E levels were detected using WB using β-actin as a loading control. The densities of the bands were measured using NIH ImageJ and normalized against β-actin. Immunoblot representative of 3 independent experiments is shown. (D) H929 cells were treated with cycloheximide (CHX; 100 μg/mL) or CHX and selinexor (100 nM) for the indicated times. Immunoblot analysis of eIF4E, c-MYC, or β-actin was performed. (E) H929 cells were treated with selinexor (50 and 200 nM) for the indicated times. Treated cells were used for mRNA extraction and reverse transcription. eIF4E mRNA levels were compared using real-time PCR. ∗P < .05. PCR, polymerase chain reaction.